98%
921
2 minutes
20
Uremic cardiomyopathy, characterized by diastolic dysfunction, left ventricular hypertrophy (LVH), and fibrosis, is a common cardiovascular complication of chronic kidney disease (CKD). Men are at a higher risk for cardiovascular and renal diseases, compared to age-matched, pre-menopausal women. We aimed to investigate the influence of sex on the severity of uremic cardiomyopathy through the characterization of functional and molecular indices of myocardial remodeling in a rat model. CKD was induced by a 5/6 nephrectomy in 9-week-old male and female Wistar rats. Serum and urine tests, transthoracic echocardiography, left ventricular (LV) histology, and quantitative reverse transcription polymerase chain reaction (RT-qPCR) were performed at week 8 or 9. Moreover, LV alterations were also tested in permeabilized cardiomyocytes (CMs) by force measurements and Western immunoblotting. CKD resulted in the development of a more severe uremic cardiomyopathy in male rats-including LVH, LV diastolic dysfunction, and fibrosis-than in female rats, where only LVH was observed. A uremic cardiomyopathy was also associated with a decrease in maximal Ca-activated force (F) in CMs of male rats. Additionally, increases in CM Ca-independent passive stiffness (F) and decreases in cardiac myosin-binding protein C (cMyBP-C) phosphorylation levels were significantly larger in male than female rats. In conclusion, a uremic cardiomyopathy involved cardiac remodeling in both sexes. Nevertheless, male rats exhibited more pronounced signs of macroscopic and microscopic alterations than their female counterparts, illustrating a sex-dependent component of uremic cardiomyopathy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11900185 | PMC |
http://dx.doi.org/10.3390/ijms26052259 | DOI Listing |
JACC Adv
August 2025
Sorbonne Université, UPMC Univ Paris 06, INSERM 1146, CNRS 7371, Laboratoire d'Imagerie Biomédicale, Paris, France; Department of Cardiovascular Imaging, Sorbonne Université, Pitié-Salpêtrière University Hospital AP-HP, Paris, France. Electronic address:
Background: Patients with end-stage renal disease (ESRD) are at high cardiovascular risk. The safety and prognostic value of stress cardiovascular magnetic resonance (CMR) in ESRD patients remains unclear as data are lacking due to perceived contrast agent-related risk.
Objectives: The authors aimed to assess the safety and prognostic value of stress CMR in asymptomatic ESRD patients on waitlist for kidney transplantation.
J Vasc Access
July 2025
Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central venous obstruction (CVO) is a common complication in hemodialysis (HD) patients that can lead to rare but potentially reversible visual impairment (VI). We report the case of a 50-year-old female with end-stage renal disease and uremic cardiomyopathy, who had received HD through a left radiocephalic arteriovenous fistula (AVF) for 6 years. She presented with progressive swelling in her left arm, chest wall, and face over the past year, along with vision loss and diplopia in the last 6 months.
View Article and Find Full Text PDFBackground: Chronic kidney disease (CKD) is an independent cardiovascular risk factor. Patients with CKD develop uremic cardiomyopathy characterized by activation of the sympathetic nervous system, left ventricular hypertrophy, and accumulation of uremic toxins such as indoxyl sulfate (IS). The aim of this study was to assess the effects of renal denervation (RDN) on uremic cardiomyopathy in a rat model of CKD.
View Article and Find Full Text PDFBMC Nephrol
July 2025
Department of Nephrology, Zhongshan Hospital, Fudan University, No.180, Fenglin Road, Xuhui District, Shanghai, 200032, China.
Background: Uremic cardiomyopathy (UCM) remains the leading cause of cardiovascular mortality in patients with end-stage renal disease (ESRD). Experimental animal models serve as essential tools for elucidating the potential mechanism underlying UCM. However, experimental UCM models are often challenged by inter-individual variability and inconsistent success rates.
View Article and Find Full Text PDFCardiol Clin
August 2025
Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Nonatherosclerotic cardiovascular disease (CVD) in chronic kidney disease (CKD) is highly prevalent and involves distinct pathophysiological mechanisms. Arteriosclerosis, characterized by medial arterial layer thickening and fibrosis, leads to increased arterial stiffness and vascular calcification, driven by disordered bone mineral metabolism. Clinical manifestations of nonatherosclerotic CVD include left ventricular hypertrophy, which occurs in up to 70% to 80% of patients with advanced CKD, heart failure (often with preserved ejection fraction), valvular heart disease, and both fatal and nonfatal arrhythmias.
View Article and Find Full Text PDF